Chinese PLA General Hospital (CAR-T cell technology) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Chinese PLA General Hospital (CAR-T cell technology) General Information
Description
Biologic cancer therapy asset. The asset consists of Chimeric Antigen Receptor T cell (CAR-T) therapy, its recombinant expression vector CD19, CD20, CD30 and human epidermal growth factor receptor's immuno-oncology patents, and phase I/II clinical data of the therapies and manufacturing knowledge. The CAR-T cell therapy involves engineering cancer patients' own immune cells to recognize and attack their tumors.
Contact Information
Corporate Office
- 28 fuxing road
- Beijing
- China
Corporate Office
- 28 fuxing road
- Beijing
- China
Chinese PLA General Hospital (CAR-T cell technology) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Chinese PLA General Hospital (CAR-T cell technology) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Chinese PLA General Hospital (CAR-T cell technology) Patents
Chinese PLA General Hospital (CAR-T cell technology) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250002911-A1 | Engineered exosome for treating hypertrophic scar (hts), and preparation method and use thereof | Pending | 30-Jun-2023 | ||
| US-20250000807-A1 | Circcdk13-enriched engineered small extracellular vesicle (e-sev), and preparation method and use thereof | Pending | 29-Jun-2023 | ||
| US-20250000911-A1 | Autophagosome for promoting healing of diabetic wound, and preparation method and use thereof | Pending | 29-Jun-2023 | ||
| US-20240325600-A1 | Porous biological amniotic membrane puncture device and preparation method | Pending | 30-Mar-2023 | ||
| US-20240033253-A1 | Photocurable hydrogel loaded with vh298-modified exosome and method of preparation and use thereof | Active | 29-Jul-2022 | A61K31/427 |
Chinese PLA General Hospital (CAR-T cell technology) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Chinese PLA General Hospital (CAR-T cell technology) FAQs
-
Where is Chinese PLA General Hospital (CAR-T cell technology) headquartered?
Chinese PLA General Hospital (CAR-T cell technology) is headquartered in Beijing, China.
-
What industry is Chinese PLA General Hospital (CAR-T cell technology) in?
Chinese PLA General Hospital (CAR-T cell technology)’s primary industry is Buildings and Property.
-
Is Chinese PLA General Hospital (CAR-T cell technology) a private or public company?
Chinese PLA General Hospital (CAR-T cell technology) is a Private company.
-
What is the current valuation of Chinese PLA General Hospital (CAR-T cell technology)?
The current valuation of Chinese PLA General Hospital (CAR-T cell technology) is .
-
What is Chinese PLA General Hospital (CAR-T cell technology)’s current revenue?
The current revenue for Chinese PLA General Hospital (CAR-T cell technology) is .
-
Who are Chinese PLA General Hospital (CAR-T cell technology)’s investors?
Chinese PLA General Hospital has invested in Chinese PLA General Hospital (CAR-T cell technology).
-
When was Chinese PLA General Hospital (CAR-T cell technology) acquired?
Chinese PLA General Hospital (CAR-T cell technology) was acquired on 09-Feb-2015.
-
Who acquired Chinese PLA General Hospital (CAR-T cell technology)?
Chinese PLA General Hospital (CAR-T cell technology) was acquired by AbelZeta.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
